NASDAQ:BDRX Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis $2.04 -0.10 (-4.72%) Closing price 03:59 PM EasternExtended Trading$2.09 +0.05 (+2.70%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BDRX alerts:Sign Up Key Stats Today's Range$2.01▼$2.1450-Day Range$2.04▼$10.6452-Week Range$2.01▼$357.60Volume8,605 shsAverage Volume27,364 shsMarket Capitalization$265.07 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for cancer and rare diseases. Its work includes both therapeutic candidates and drug-delivery technologies intended to help medicines reach their target tissues. The company’s development portfolio has included MTX110, a formulation of the cancer drug panobinostat being investigated for brain tumors, and eRapa, an oral formulation of rapamycin being studied for familial adenomatous polyposis, a rare inherited condition that can lead to colorectal cancer. These are investigational products and are not approved treatments. Biodexa was formerly known as Midatech Pharma and has roots in the United Kingdom. It has conducted development activities across the United Kingdom and the United States.AI Generated. May Contain Errors. Read More Biodexa Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreBDRX MarketRank™: 0.656388851485 of 5 starsBiodexa Pharmaceuticals scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBiodexa Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBiodexa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Biodexa Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioBiodexa Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.46% of the float of Biodexa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBiodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodexa Pharmaceuticals has recently decreased by 99.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiodexa Pharmaceuticals does not currently pay a dividend.Dividend GrowthBiodexa Pharmaceuticals does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.Percentage Held by Institutions17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.Read more about Biodexa Pharmaceuticals' insider trading history. Receive BDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDRX Stock News HeadlinesBiodexa provides R&D UpdateNovember 9, 2026 | globenewswire.comBiodexa Pharmaceuticals PLC - Depositary receipt price target increased by 700.00% to $73.44November 2, 2026 | msn.comThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.November 18 at 1:00 AM | Porter & Company (Ad)Biodexa Enrolls 100 Patients In Phase 3 ERapa Trial For FAPOctober 13, 2026 | rttnews.comBiodexa reaches 100-patient enrollment milestone in phase 3 Serenta trial as key analysis timeline acceleratesOctober 13, 2026 | msn.comBiodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAPOctober 13, 2026 | globenewswire.comBDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 PatientsSeptember 22, 2026 | finance.yahoo.comBiodexa Enters Warrant Exercise Deal For $2 Mln As Phase 3 For ERapa Progresses; Stock Plunges 25%September 16, 2026 | rttnews.comSee More Headlines BDRX Stock Analysis - Frequently Asked Questions How have BDRX shares performed this year? Biodexa Pharmaceuticals' stock was trading at $90.80 at the start of the year. Since then, BDRX stock has decreased by 97.8% and is now trading at $2.0390. How were Biodexa Pharmaceuticals' earnings last quarter? Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) released its quarterly earnings results on Thursday, September, 10th. The company reported ($640,000.00) earnings per share for the quarter. When did Biodexa Pharmaceuticals' stock split? Biodexa Pharmaceuticals's stock reverse split on Monday, April 6th 2026.The 1-5 reverse split was announced on Wednesday, March 18th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Biodexa Pharmaceuticals? Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biodexa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biodexa Pharmaceuticals investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), NIO (NIO), Nokia (NOK), Nikola (NKLAQ), Advanced Micro Devices (AMD) and Corbus Pharmaceuticals (CRBP). Company Calendar Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BDRX's financial health is in the Red zone, according to TradeSmith. BDRX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BDRX Previous SymbolLON:MTPH CIK1643918 Webwww.biodexapharma.com Phone441235888300FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.41 Quick RatioN/A Sales & Book Value Annual Sales$470 thousand Price / Sales0.56 Cash FlowN/A Price / Cash FlowN/A Book Value$882.39 per share Price / Book0.00Miscellaneous Outstanding Shares130,000Free Float129,000Market Cap$265.07 thousand OptionableNot Optionable Beta1.25 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BDRX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.